KromaTiD Announces Launch of New Product, dGH In-Site™

LONGMONT, Colo., June 9, 2020 /PRNewswire/ — KromaTiD, Inc. announced today the launch of its new product dGH In-Site™, a single-cell, high resolution, genome-wide DNA insert tracking assay. dGH In-Site™ enables researchers to directly measure the degree of DNA integration at a target while at the same time measuring off-target integration.   In-Site provides a comprehensive high-specificity measurement of small DNA inserts that is not possible with any other method. 

KromaTiD CEO, Christopher Tompkins, PhD, said of the in-Site platform: “We have always focused on providing custom dGH solutions to gene editing and pharmaceutical companies.  dGH In-Site is the first of our standardized, genome-wide dGH products supporting the entire engineered cell markets.  This is data that can help optimize your processes, understand the success of your edits and speed your engineered cell products to market.”

Learn more in the press release.

Categories: Ecosystem News